CJC-1295 without DAC (Mod GRF 1-29)
Sourcing GuideSourcing CJC-1295 without DAC (Mod GRF 1-29) from research-grade vendors requires the QC framework that governs any peptide procurement: certificate of analysis review, lot-specific verification, third-party laboratory issuance, and — critically — endotoxin testing for injectable material. The short-acting version of CJC-1295 — same GHRH stimulation, but daily dosing produces a more physiological GH pulse pattern. The three-tier vendor market (pharmaceutical-grade compounded, reputable research-grade, grey-market) is described below.
Key Takeaways
Procurement lens: CJC-1295 without DAC (Mod GRF 1-29) sourcing requires lot-specific COA, HPLC purity ≥98%, mass spec confirmation matching ~3367 Da. Mechanism: Same GHRH-receptor agonism as DAC variant. Storage: lyophilised at -20°C for 18-24 months; reconstituted at 4°C for 14-28 days. Vendor tier: pharmaceutical-grade compounded > reputable research-grade > grey-market (3-5x cost differential; quality differential substantially larger). Sourcing-validated stack partners: BPC-157, TB-500, GHK-Cu.
For procurement of CJC-1295 without DAC (Mod GRF 1-29), the relevant QC framework covers analytical purity (HPLC), structural identity (mass spec), microbiological safety (endotoxin), and stoichiometric correctness where applicable. Same GHRH-receptor agonism as DAC variant. Four amino acid substitutions resist enzymatic cleavage. Without the albumin-binding tail, the molecule clears in roughly half an hour — useful for evening dosing that mimics natural sleep-time GH pulse. The subsections below address each QC layer and the vendor-tier landscape.
HPLC purity and analytical identity
Minimum acceptable HPLC purity for CJC-1295 without DAC (Mod GRF 1-29) is ≥98% in research-grade material. Mass spec confirmation should show the characteristic m/z of ~3367 (M+H)+. Contaminant peaks above 1% in the HPLC trace warrant quantification on the COA and — ideally — structural identification of the major impurities.
COA evaluation and red flags
Acceptable CJC-1295 without DAC (Mod GRF 1-29) certificates of analysis specify: (1) lot number matching the vial, (2) HPLC purity with chromatographic trace, (3) mass spec confirmation, (4) endotoxin testing for SubQ-route use, and (5) issuance from an accredited third-party laboratory. Template COAs that cannot be traced to a specific lot, COAs missing endotoxin data for injectable material, and COAs issued by the vendor's own laboratory rather than a third party are all sourcing red flags.
Reconstitution and storage protocols
CJC-1295 without DAC (Mod GRF 1-29) is typically supplied lyophilised in glass vials for reconstitution with bacteriostatic water. Standard reconstitution: dissolve at 1–2 mg/mL, store reconstituted material at 4°C, and use within 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Lyophilised storage at −20°C extends shelf life to 18–24 months for most peptides in this class.
Pharmaceutical-grade compounded CJC-1295 without DAC (Mod GRF 1-29) is the lowest-risk sourcing path for gmp vs research grade use where the route permits, particularly for users with clinical supervision. Research-grade material from accredited vendors is the practical alternative; grey-market sourcing is not appropriate for this application.
Sourcing CJC-1295 without DAC (Mod GRF 1-29) for lyophilisation quality use requires the same QC discipline as any peptide procurement: lot-specific COA, HPLC purity ≥98%, mass spec confirmation, endotoxin testing for injectable routes. Application-specific use does not relax the sourcing standard.
For users targeting mass spectrometry verification, the sourcing question is whether the chosen vendor consistently delivers analytical-spec material across lots. Repeated re-orders from the same vendor with mid-cycle COA spot-checks is the procurement pattern that catches lot drift before it affects results.
Pharmaceutical-grade compounded CJC-1295 without DAC (Mod GRF 1-29) is the lowest-risk sourcing path for vial inspection use where the route permits, particularly for users with clinical supervision. Research-grade material from accredited vendors is the practical alternative; grey-market sourcing is not appropriate for this application.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 100 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 60 mcg | 4–6 weeks initial cycle |
| Sourcing Guide focus | SubQ | 100 mcg | 1-3x daily SubQ |
| Maintenance phase | SubQ | 70 mcg | Ongoing with periodic pauses |
Dose timing for CJC-1295 without DAC (Mod GRF 1-29) is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.
CJC-1295 without DAC (Mod GRF 1-29) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from experienced peptide buyers.
- CJC-1295 without DAC (Mod GRF 1-29) + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in sourcing / quality / procurement protocols.
- CJC-1295 without DAC (Mod GRF 1-29) + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in sourcing / quality / procurement protocols.
- CJC-1295 without DAC (Mod GRF 1-29) + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in sourcing / quality / procurement protocols.
- CJC-1295 without DAC (Mod GRF 1-29) + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in sourcing / quality / procurement protocols.
Short half-life produces fewer sustained-IGF-1 concerns than DAC variant. Site reactions common. Stack with ipamorelin for synergy.
Lens-specific safety considerations for sourcing / quality / procurement use of CJC-1295 without DAC (Mod GRF 1-29): Short half-life produces fewer sustained-IGF-1 concerns than DAC variant. Site reactions common. Stack with ipamorelin for synergy. Additional sourcing / quality / procurement monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| CJC-1295 without DAC (Mod GRF 1-29) | Short-acting GHRH analogue | ~30 min | Sourcing Guide |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
Storage protocol?
Vendor red flags?
Pharmaceutical-grade versus research-grade?
Lot variability across orders?
How does CJC-1295 without DAC (Mod GRF 1-29)'s half-life affect dosing?
Should I cycle CJC-1295 without DAC (Mod GRF 1-29)?
Start a CJC-1295 without DAC (Mod GRF 1-29) Protocol
Alukard provides GMP-certified physician-supervised sourcing with GMP-certified CJC-1295 without DAC (Mod GRF 1-29) and Pharmaceutical-grade compounds with full COA documentation.
Get ProtocolQuick Facts
- Molecular weight
- ~3367 Da
- Sequence length
- 29 aa
- Half-life
- ~30 min
- WADA
- Banned (S2 class)
- FDA
- Unapproved
- Research
- Mechanistic studies; off-label use widespread
Stack Partners
All sourcing / quality / procurement applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for CJC-1295 without DAC (Mod GRF 1-29) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Sourcing / Quality / Procurement Protocol for CJC-1295 without DAC (Mod GRF 1-29)
Alukard provides GMP-certified physician-supervised sourcing with Pharmaceutical-grade compounds with full COA documentation.
HIPAA Compliant · GMP Certified · Physician Supervised